Loading…
Based on limited metadata, the FDA issued a Warning Letter to Skylark CMC Pvt. Ltd. on December 3, 2018, regarding manufacturing or regulatory compliance issues. While the specific subject line and detailed violation count are unavailable, the letter appears to address concerns related to Chemistry, Manufacturing, and Controls (CMC) operations, which typically involve drug manufacturing practices, quality control, or product specifications. Without access to the full letter text or identification of the specific issuing office, the precise regulatory scope and nature of the violations cannot be determined from the metadata alone.